CD274 and hypothyroidism: Hypothyroidism is the most frequent presentation (3.9–8.5%), preceded by destructive thyroiditis in 30–40% of patients treated with anti-PD-1/anti-PD-L1, and two thirds of patients under combined treatment [27,42].